Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?
Purpose This multicenter retrospective study assessed the real-world effectiveness and safety of upadacitinib in adults with moderate-to-severe atopic dermatitis across eight centers in central Italy.Materials and methods A total of 150 patients received upadacitinib 15 mg or 30 mg daily as monother...
Saved in:
| Main Authors: | Edoardo Mortato, Niccolò Gori, Giacomo Caldarola, Marina Talamonti, Claudia Paganini, Luisa Boeti, Filomena Russo, Teresa Grieco, Ersilia Tolino, Gaia Moretta, Flavia Pigliacelli, Rosa Coppola, Domenico Giordano, Camilla Chello, Concetta Potenza, Maria Concetta Fargnoli, Vincenzo Panasiti, Barbara Cocuroccia, Ketty Peris, Marco Galluzzo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2509541 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rosacea-like eruptions associated with upadacitinib in atopic dermatitis: two case reports and management strategies
by: Claudia Paganini, et al.
Published: (2025-03-01) -
Experience of using the drug upadacitinib in a child with severe atopic dermatitis
by: G. D. Alemanova, et al.
Published: (2025-06-01) -
Treatment of Moderate-to-severe Atopic Dermatitis with Upadacitinib: Results from an Interim Analysis of the TREATgermany Registry
by: Barbara Kind, et al.
Published: (2025-05-01) -
Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study
by: Tiago Torres, et al.
Published: (2025-06-01) -
A Case of Upadacitinib-Associated Ileus Secondary to Psoriasis Induced by Treatment of Atopic Dermatitis with Dupilumab
by: Liu X, et al.
Published: (2024-12-01)